HOUSTON--(BUSINESS WIRE)--CorInnova Inc., an emerging medical device company developing novel technology for the treatment of Heart Failure, announced today three milestone events: (1) the Company has received notice of allowance of a seminal patent to protect its intellectual property associated with the world’s first minimally invasively-delivered soft robotic heart device to support heart function; (2) the Company has become a resident at Johnson & Johnson Innovation, JLABS @ TMC; (3) this residency follows a $6.1 million funding from the Wellcome Trust, details of which have not been disclosed.
“Our EpicHeartTM technology is innovative and groundbreaking. We believe it will lead to a new paradigm for heart failure treatment,” said William Altman, CEO of CorInnova.
The technology includes the following features:
Ad Statistics
Times Displayed: 22281
Times Visited: 445 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
First collapsible and self-expanding thin film soft robotic device for cardiac assist;
Rapid minimally invasive implantation ability and simple delivery tool;
Intrinsic pneumatic attachment inside the pericardial sac (no sutures or incisions to the heart or aorta);
Non-blood-contacting device operation;
Likelihood of up to 30-40% fewer adverse events than blood-contacting assist devices;
Biventricular (or normal left ventricular) assist capability;
Non-obligatory operation;
Promotion of heart rehabilitation by promoting correct cardiac motion;
The potential to prevent the development of heart failure after major heart attacks.
CorInnova’s operations are located at Johnson & Johnson Innovation, JLABS at the Texas Medical Center (JLABS @ TMC). JLABS is a 34,000 square-foot life science innovation center located in Houston. The labs provide a flexible environment for start-up companies pursuing new technologies and research platforms to advance medical care. Through a "no strings attached" model, JJI does not take an equity stake in the companies occupying JLABS, and the companies are free to develop products - either on their own, or by initiating a separate external partnership with JJI or any other company. CorInnova’s residency at JLABS @ TMC follows a $6.1 million funding from the Wellcome Trust, details of which have not been disclosed.
“Wellcome is pleased to support the development of this innovative technology for the treatment of congestive heart failure,” said Dr. Philip Jordan from Wellcome’s Innovations team. “Congestive heart failure is a chronic condition that affects roughly six million people in the US alone and is a leading cause of death and disability. A significantly less-invasive medical device that could restore a certain level of heart function would be potentially transformative for patients,” added Dr. Jordan.
